STOCKS TELEGRAPH

Tag: Enochian stock

  • Is ENOB Stock Surging For A Reason?

    Is ENOB Stock Surging For A Reason?

    Shares of the biopharmaceutical company Enochian Biosciences Inc. (ENOB) are rising 5.51% to trade at $5.55 at the commencement of today’s regular session. Enochian stock has risen as high as 16.73% to $6.14 on the stock charts in the premarket session. ENOB stock closed the Friday session at $5.26, increasing 6.26% on the day. ENOB stock traded for 0.58 million shares, lower than the 2.19 million average volume over the last three months. During the last trading session, the ENOB stock oscillated between a price range of $4.88 and $5.31. EPS for the ENOB stock was negative 0.29.

    ENOB is up 4.78% in the last five sessions and gained 22.33% over the past month while jumping 78.31% so far this year. Currently, ENOB’s 50-day moving average is $4.49, higher than its 200-day moving average of $3.67. Furthermore, the ENOB stock is currently trading at an RSI of 54.91. The ENOB stock is rising sharply on news that FDA has accepted its Pre-IND request for its treatment of hepatitis.

    Which therapy is ENOB trying to develop?

    Enochian is a biopharmaceutical company focusing on the development of gene-modified cellular and immune therapies for the potential cure and treatment of deadly diseases. In addition to HIV/AIDS, Hepatitis B, Corona and Influenza viruses, and Oncology, ENOB’s gene-modified cell, and immune therapy platforms might also be useful for other indications.

    The FDA accepted an IND (Investigational New Drug) request from Enochian for a potential cure of hepatitis B virus (HBV), announced the company in a press release today.

    • Commentary will be provided in writing this fall.
    • A proof-of-concept study performed in chimeric mice substantiated ENOB’s pre-IND request.
    • Researchers have deemed ENOB’s study as the best way to evaluate HBV cure using an animal model.
    • A request from ENOB for feedback on its Hepatitis B program was accepted by the FDA.
    • The agency’s suggestions were appreciated by ENOB.
    • ENOB’s move toward pre-IND is also brought about by Hijack RNA, which exhibits an intriguing mechanism of action.
    • In addition to being a potential platform technology for coronaviruses (including COVID-19), influenza and HBV, the mechanism is being explored as a potential technology for combating HIV.
    • With the impressive results of the premier animal model, ENOB has great hope of developing a commercial product that may cure chronic liver damage in approximately 350 million people per year, killing nearly 1 million.

    What has ENOB recently shared about HBV therapy?

    Enochian (ENOB) co-founder and inventor Serhat Gumrukçu, director of Seraph Research Institute (SRI), has recently presented data showing the daily decline of HBV to the point where it cannot be detected by day eight. The liver and other tissues were not found to be toxic by ENOB. ENOB presented its findings during the prestigious International Liver Conference last month.

  • Why Enochian Biosciences, Inc. (ENOB) stock is climbing today?

    Why Enochian Biosciences, Inc. (ENOB) stock is climbing today?

    Enochian Biosciences, Inc. (ENOB) stock announced the acquisition of an exclusive license for innovative technology in order to fight against various variants that cause coronavirus as well as influenza after which the ENOB stock price happened to green and saw a push of 10.86% a share as of this writing. The stock was down in the previous trading session and dropped by 1.86% at closing. Let’s check out more about the ENOB stock.

    What’s Happening?

    Dr. Serhat Gumrukçu developed the novel treatment in which the part of the virus is tricked in order to treat the infection at a rapid rate and protect all kinds of future variants of COVID-19 and influenza as well. This treatment could be effective for longer periods due to the large living time span of 20 months by target viruses cell in human airways. The tricked part of the virus is similar to all SARS-CoV-2 variants as well as COVID-19 viruses that affect humans and also have the same origin as all influenza viruses since 1918. Enochian Biosciences will submit the Pre-Investigator New Drug meeting request for COVID-19 treatment to the U.S Food and Drug Administration near in the future.

    The roll-out of vaccines around the globe has fortunately lessened the impact of COVID-19 but there are chances of mutation that could escape from the effect of current vaccines. Furthermore, there is a lot of effort is required to provide easy and effective treatment to cope with this pandemic. The potential treatment discussed above has the potential to stop the current pandemic effect as well as to prevent future variants of COVID-19 along with the influenza virus.

    Development in HIV:

    The ENOB’s licensed proprietary technology intended for the treatment of HIV in individuals via a cell therapy is moving close to the FDA approval as the FDA has accepted the pre-IND meeting request which would enable the Director of the Seraph Research Institute (SRI), Dr. Serhat Gumrukcu and his team to present the HIV cell therapy to FDA. This innovative cellular therapy could prove to be a functional cure for patients suffering from HIV and would allow them to stop the conventional antiviral treatment for longer periods.

    Conclusion:

    ENOB stock is climbing today as the investors are responding positively to the acquisition of the exclusive license for potential coronavirus and influenza inhaled treatment and prevention technology. The stock is progressing in its mission to treat patients suffering from HIV via innovative cellular therapy. In short, ENOB stock can be a good bet for investors in the long run.